InvestorsHub Logo
Followers 28
Posts 398
Boards Moderated 0
Alias Born 12/10/2015

Re: None

Thursday, 08/25/2022 5:58:51 PM

Thursday, August 25, 2022 5:58:51 PM

Post# of 458279
https://www.drugdiscoverynews.com/a-drug-that-protects-against-alzheimer-s-disease-may-help-with-wolfram-syndrome-15484

The team behind the new study didn’t pick an S1R agonist to test out of thin air. They previously showed that the S1R agonist blarcamesine protected mice against Alzheimer’s disease, a neurodegenerative condition partially caused by mitochondrial dysfunction and increased ER-mitochondrial contact (2). The drug, produced by Anavex Life Sciences, is currently undergoing a phase III clinical trial to test its efficacy in patients with Alzheimer’s disease and a phase II trial in patients with Parkinson’s disease, another neurological condition with etiology linked to misbehaving mitochondria.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News